Piramal Healthcare invests $2.5 million to further expand commercial ADC capacity

By Piramal

Piramal’s healthcare vertical has announced that it is to invest $2.5 million at its FDA-approved site in Grangemouth, UK, to upgrade one of its antibody drug conjugate (ADC) manufacturing suites from clinical phase to commercial grade in response to customer demand.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.